OncoMatch/Clinical Trials/NCT07404176
Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors
Is NCT07404176 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Terbium 161 for neuroendocrine neoplasms (tumours).
Treatment: Terbium 161 — Gastro-enteropancreatic Neuro-endocrine tumors (GEP-NETs) are rare slow-growing cancers which commonly involve the abdominal organs like liver, stomach, intestines and pancreas. Their incidence has been documented to have increased over the last decade, thus resulting in treatment options being developed to treat these cancers. These cancers spread commonly to the liver, followed by lungs, bones and other sites. Depending on the extent of disease seen on scan, treatment is planned. Patients are advised Peptide Receptor Radionuclide Therapy (PRRT), which is the current standard of treatment for metastatic GEP-NETs. Radio-isotopes labeled to octreotide analogs bind to somatostatin receptors on surface of cancer cells and deliver radiation to the cancer cells when injected into the body. Lu-177 (Lutetium-177) is one such radioisotope which has been used for tagging to the octreotide and is known as Lu-177 DOTATATE PRRT, which is now routinely used in clinical practice. Terbium-161 is another radioisotope which can be labeled to octreotide and used for PRRT. It has advantages over Lu-177 such that it specifically reaches the tumor sites and does not affect the surrounding normal cells, due to its higher penetrating capacity and shorter range of travel. This will benefit patients as the effectiveness of PRRT will be higher with lesser side effects. However, the investigators can only do this by performing a study. Response to treatment can be evaluated by performing scans and side effects, if any can be studied by performing blood tests.
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroendocrine Tumor
Performance status
KARNOFSKY OR ECOG 60–2
Karnofsky performance-status score of at least 60 or ECOG performance status <=2
Prior therapy
Must have received: peptide receptor radionuclide therapy (Lu-177 DOTATATE)
Patient who have shown disease progression with Lu-177 DOTATATE PRRT
Lab requirements
Blood counts
Hemoglobin level of less than 8.0 g per deciliter; Red blood cell count less than 300,000/cubic millimeter; White cell count of less than 2000 per cubic millimeter; Platelet count of less than 75,000 per cubic millimetre
Kidney function
Serum creatinine level of more than 1.6 mg/dl or a creatinine clearance of less than 50 ml/min
Liver function
Total bilirubin level of more than 3 times the upper limit of the normal range
Serum creatinine level of more than 1.6 mg/dl or a creatinine clearance of less than 50 ml/min; Hemoglobin level of less than 8.0 g per deciliter; Red blood cell count less than 300,000/cubic millimeter; White cell count of less than 2000 per cubic millimeter; Platelet count of less than 75,000 per cubic millimetre; Total bilirubin level of more than 3 times the upper limit of the normal range
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify